Patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment plus placebo

patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + Silymarin Oral 420mg/day in 3 divided doses

COVID-19

Viral Pneumonia Human Coronavirus

Silymarin Oral at a dose of 420 mg/day in 3 divided doses.

Silymarin

Placebo

Cairo University

Silymarin in COVID-19 Pneumonia

Trial of Silymarin in Adults With COVID-19 Pneumonia

Defined as the time from randomization to an improvement of two points (from the status of randomization) on seven category ordinal scale or live discharge from the hospital, whichever comes first.

Clinical status as assessed with the seven-category ordinal scale on days 7 and 14

number of days patient remained with positive RT-PCR SARS-CoV-2 swab

Any adverse events whether related to medication or not

Khaled Mohammed Korany Salem

Assistant Lecturer

Group 1 (Control): Includes 25 patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + placebo Group 2 (Intervention): Includes 25 patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + Silymarin Oral at a dose of 420 mg/day in 3 divided doses.

30 patients receiving blood transfusion and taking iron-chelating therapy along with metformin tablets (500 mg once daily for the first week then twice daily for 6 months).

30 patients receiving blood transfusion and taking iron-chelating therapy.

Beta Thalassemia Major Anemia

Metformin

Abo El Reesh Hospital

El Demerdash (Ain Shams Teaching Hospital).

The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major

The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalasemia Major

Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST).

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Fibroscan will be done for each patient before and at the end of the study.

Mona Sobhy Abd El-Mon'em Gaber

Teaching assistant-faculty of pharmacy-Cairo University

20 mg/kg Silibinin (Legalon SIL) ,as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.

Placebo (saline), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.

Hepatitis C Virus Recurrence

20 mg/kg Silibinin (Legalon SIL), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.

Silibinin (Legalon-SIL)

Saline

Azienda Ospedaliero-Universitaria Policlinico Consorziale

Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of LEGALON SIL for the Treatment of HCV Recurrence in Stable Liver Transplanted Patients

To determine the effect of post-transplant treatment with Legalon SIL on HCV viral load 30 days after the beginning of treatment.

To determine the effect of post-transplant treatment with Legalon SIL on HCV viral load and lymphocyte activation one year after the beginning of treatment.

To determine the effect of post-transplant treatment with Legalon SIL on fibrosis and functional state.

To determine the safety and tolerability of post-transplant treatment with Legalon SIL, including evaluation of its effect on the levels of immunomodulators.

silymarin/nekroz

Silymarin in COVID-19 Pneumonia

The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major

Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası